{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ara+C&page=3", "query": { "intervention": "Ara C", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 905, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ara+C&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ara+C&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T03:09:41.865Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06788756", "title": "L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Myeloid Leukaemia (AML)" ], "interventions": [ { "name": "Placebo in combination with Cytarabine Injection", "type": "DRUG" }, { "name": "Liposomal Annamycin Injection in combination with Cytarabine Injection", "type": "DRUG" }, { "name": "Liposomal Annamycin for Injection in combination with Cytarabine Injection.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Moleculin Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 312, "start_date": "2025-03-12", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06788756" }, { "nct_id": "NCT00715637", "title": "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Secondary Acute Myeloid Leukemia (Secondary AML, sAML)" ], "interventions": [ { "name": "Daunorubicin and Cytarabine", "type": "DRUG" }, { "name": "Amonafide and Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Antisoma Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2007-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-10-13", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 30, "location_summary": "Los Angelas, California • Los Angeles, California • San Francisco, California + 24 more", "locations": [ { "city": "Los Angelas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00715637" }, { "nct_id": "NCT01861002", "title": "A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute, Childhood", "Myelogenous Leukemia, Acute, Childhood" ], "interventions": [ { "name": "Azacytidine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Intrathecal (IT) Cytarabine", "type": "DRUG" }, { "name": "Intrathecal Methotrexate (IT MTX)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 15, "start_date": "2013-05-22", "completion_date": "2014-07-28", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 19, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01861002" }, { "nct_id": "NCT00866918", "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Childhood Acute Promyelocytic Leukemia With PML-RARA", "Myeloid Neoplasm" ], "interventions": [ { "name": "Arsenic Trioxide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Tretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 106, "start_date": "2009-03-09", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2022-10-25", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 112, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866918" }, { "nct_id": "NCT06001788", "title": "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML", "AML With Mutated NPM1", "Hematologic Malignancy", "KMT2Ar", "NPM1 Mutation", "MLL Rearrangement", "Leukemia", "Acute Myeloid Leukemia", "Leukemia, Myeloid", "Leukemia, Myeloid, Acute", "Acute Leukemia", "Neoplasms by Histologic Type" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Granulocyte colony-stimulating factor", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2024-02-22", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 38, "location_summary": "Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06001788" }, { "nct_id": "NCT02768792", "title": "High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia, in Relapse" ], "interventions": [ { "name": "pembrolizumab,", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 38, "start_date": "2016-08-22", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Chapel Hill, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02768792" }, { "nct_id": "NCT05030831", "title": "Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ATP-Binding Cassette Subfamily C Member 6 Deficiency", "Pseudoxanthoma Elasticum", "Generalized Arterial Calcification of Infancy" ], "interventions": [ { "name": "INZ-701", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inozyme Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 10, "start_date": "2022-04-11", "completion_date": "2024-07-09", "has_results": false, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 1, "location_summary": "Eatontown, New Jersey", "locations": [ { "city": "Eatontown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05030831" }, { "nct_id": "NCT02665065", "title": "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Leukemia, Acute Myeloid", "Myeloid Leukemia, Acute", "Leukemia, Myeloid, Acute", "Acute Myelogenous Leukemia", "Leukemia, Acute Myelogenous", "Myelogenous Leukemia, Acute", "AML", "Bone Marrow Transplant" ], "interventions": [ { "name": "Iomab-B", "type": "DRUG" }, { "name": "Conventional Care", "type": "DRUG" }, { "name": "HCT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Actinium Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 153, "start_date": "2016-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 22, "location_summary": "Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02665065" }, { "nct_id": "NCT00483067", "title": "2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "2-CdA", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "G-CSF (Granulocyte colony-stimulating factor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "76 Years", "sex": "ALL", "summary": "Up to 76 Years" }, "enrollment_count": 13, "start_date": "1998-03", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2012-08-02", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00483067" }, { "nct_id": "NCT07032727", "title": "Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Targeted Therapy", "IDH1-Mutated Malignancies", "Mutations" ], "interventions": [ { "name": "Olutasidenib", "type": "DRUG" }, { "name": "Cladribine (CLAD)", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2025-09-12", "completion_date": "2029-06-01", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-02T03:09:41.865Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07032727" } ] }